

How brain functioning affects the results of transcranial magnetic stimulation treatment

| | | |
|--|---|---|
| Submission date 22/08/2025 | Recruitment status Recruiting | <input checked="" type="checkbox"/> Prospectively registered |
| | | <input type="checkbox"/> Protocol |
| Registration date 28/08/2025 | Overall study status Ongoing | <input type="checkbox"/> Statistical analysis plan |
| | | <input type="checkbox"/> Results |
| Last Edited 09/09/2025 | Condition category Mental and Behavioural Disorders | <input type="checkbox"/> Individual participant data |
| | | <input checked="" type="checkbox"/> Record updated in last year |

Plain English summary of protocol

Background and study aims

The symptoms of depression can be complex and vary widely between people. If you're depressed, you may feel sad, hopeless and lose interest in things you used to enjoy. Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. TMS is typically used when medication hasn't been effective.

This study aims to test whether a new TMS protocol, including individual imaging-based targeting, improves outcomes in depression.

Who can participate?

Patients aged 18 to 67 years referred to the Helsinki University Central Hospital for rTMS for major depressive disorder (MDD)

What does the study involve?

The study involves a 2-hour visit to Aalto University Advanced Magnetic Imaging Centre for magnetic resonance imaging (MRI). This is followed by a 1-2-hour meeting including definition of dose and possible targets for the treatment. A nurse uses a randomized list to select the protocol, and the participants and the researchers who evaluate the outcome will not know the method. TMS is delivered five times a week for up to 20 sessions and combined with brief cognitive tasks and questionnaires.

What are the possible benefits and risks of participating?

Possible benefits of the study include improved outcomes of rTMS treatment and risks resemble those of usual TMS treatment, including uncomfortable stimulation site sensations and a small risk of seizure.

Where is the study run from?

Helsinki University Central Hospital Department of Psychiatry (Finland)

When is the study starting and how long is it expected to run for?

January 2023 to May 2028

Who is funding the study?

1. Research Council of Finland
2. Finnish government funding for health care research
3. Helsinki and Uusimaa Hospital District

Who is the main contact?

Dr Tuukka Raij, tuukka.raij@hus.fi

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr Tuukka Raij

ORCID ID

<https://orcid.org/0000-0002-9834-5570>

Contact details

Valskarinkatu 12
PO Box 590
Helsinki
Finland
00290 HUS
+358 (0)504285473
tuukka.raij@hus.fi

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

7111

Study information

Scientific Title

Effect of cognition and target model optimization on outcome of Helsinki individual transcranial magnetic stimulation treatment

Acronym

HIT3

Study objectives

New protocol results in better outcome than regular transcranial magnetic stimulation (TMS)

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 25/06/2025, HUS regional medical research ethics committee (HUS Keskuskirjaamo, Helsinki, PO Box 200, Finland; +358 (0)403594618; eettiset.toimikunnat@hus.fi), ref: HUS/12135/2022

Study design

Interventional double-blind randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment, Efficacy

Health condition(s) or problem(s) studied

Major depressive disorder, resistant to at least two antidepressants

Interventions

Participants are randomized 1:1 to receive transcranial magnetic theta burst stimulation with:

1. Regular theta burst protocol
2. New protocol including individually planned targeting

Each group is further divided 1:1 to a cognitive priming task or no task.

The research nurse who delivers treatment uses balanced lists for randomization, while researchers who evaluate the outcome and the patient remain blind to the treatment arm. Theta burst stimuli are delivered at 120% (or nearest tolerated) of motor threshold five times a week for 20 days.

Intervention Type

Device

Phase

Phase III

Drug/device/biological/vaccine name(s)

Transcranial magnetic stimulation

Primary outcome(s)

Severity of depression measured using the Montgomery Åsberg Depression Rating Scale (MADRS) rated before and within 2 weeks after treatment

Key secondary outcome(s)

1. Functioning measured using the Social and Occupational Functioning Scale (SOFAS) before and within 2 weeks after treatment
2. Severity of depression measured using the self-evaluated Patient health questionnaire (PHQ-9) before and within 2 weeks after treatment and 6 weeks after treatment

3. Remission defined as MADRS <11 within 2 weeks after treatment
4. Response defined as MADRS within 2 weeks after treatment >50 % less than MADRS before treatment

Completion date

31/05/2028

Eligibility

Key inclusion criteria

1. Diagnosis of major depressive disorder (DSM-IV) as the principal diagnosis with Patient Health Questionnaire-9 score >14
2. Inability to tolerate antidepressant medication or unresponsiveness to minimum of 2 months trial with adequate dose of antidepressant
3. No change in antidepressive medication in 4 weeks prior to treatment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

67 years

Sex

All

Key exclusion criteria

1. Previous rTMS treatment
2. Borderline personality features exceeding 7 points in McLean Screening Instrument for Borderline Personality Disorder, or other somatic or psychiatric conditions that likely interfere with recovery from depression with TMS (an unstable medical illness, substantial neurological illness, chronic pain, psychotic disorder or current psychotic symptoms, substance abuse or dependency within last 3 months, >2 mg lorazepam equivalents benzodiazepine use daily or any anticonvulsant, or lifetime history of non-response to an adequate course - i.e., a minimum of eight treatments - of electroconvulsive therapy)
3. Patients with safety risks including active suicidality, pregnancy, magnetic metal or leads in the upper body, or history of seizures

Date of first enrolment

15/09/2025

Date of final enrolment

31/12/2027

Locations

Countries of recruitment

Finland

Study participating centre

Helsinki University Central Hospital Department of Psychiatry

Valskarinkatu 12

PO Box 590

Helsinki

Finland

00029 HUS

Sponsor information

Organisation

Hospital District of Helsinki and Uusimaa

ROR

<https://ror.org/020cpqb94>

Funder(s)

Funder type

Government

Funder Name

Research Council of Finland

Alternative Name(s)

Academy of Finland, Suomen Akatemia, Finlands Akademi, AKA

Funding Body Type

Government organisation

Funding Body Subtype

Research institutes and centers

Location

Finland

Funder Name

Helsinki and Uusimaa Hospital District

Funder Name

Government of Finland

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the need to protect privacy of the participants.

IPD sharing plan summary

Not expected to be made available